Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-27
    E.g., 2018-06-27

Articles

19281 items
12:00 AM, Jul 06, 1993  |  BioCentury | Strategy

Little thought required

Little thought required Acting to salvage its $100 million investment in Centocor Inc., Eli Lilly and Co. exercised its option on CNTO's CentoRx monoclonal antibody. However, the decision to exercise the option was obvious, and...
12:00 AM, Jul 06, 1993  |  BioCentury | Strategy

Bristol-Myers Chooses lxsys

Bristol-Myers chooses Ixsys Despite the lackluster track record of therapeutic monoclonal antibodies, Bristol-Myers Squibb is reinforcing its decade-long MAb program with a three-year collaboration with Ixsys Inc. to develop treatments for solid tumors. Bristol-Myers will provide...
12:00 AM, Jul 06, 1993  |  BioCentury | Product Development

Cortech Adopts Apache lll

Cortech adopts Apache III Cortech Inc. has become the second company to adopt the Apache III data base to derive a risk model for patients enrolling in sepsis trials. CRTQ filed with the FDA a...
12:00 AM, Jul 06, 1993  |  BioCentury | Finance

'Quasi-public' route in hard market times

Like the two ends of a seesaw, private placements of stock tend to go up as the availability of public financing goes down. But when buyers are reluctant to get on that ride, companies and...
12:00 AM, Jun 28, 1993  |  BioCentury | Strategy

Near-term prospects for gene therapy

Near-term prospects for gene therapy Despite increasing attention to the potential of in vivo gene therapies, the near-term opportunities will continue to be ex vivo autologous treatments, according to executives at Somatix Therapy...
12:00 AM, Jun 28, 1993  |  BioCentury | Strategy

Less is less

Biotechnology companies, groping for alternatives to the closed financing window, are likely to find partnership deals harder to come by over the next six to 12 months, and with less favorable terms than in the...
12:00 AM, Jun 28, 1993  |  BioCentury | Strategy

1993 deal flow

1993 deal flow American Cyanamid Cambridge Bio QS-21 vaccine adjuvant Houghten screening for herbicides, pesticides and veterinary products Upjohn Biogen cell adhesion molecules Gensia generic cancer therapeutics Syntex Agouron arthritis, cancer Hoffmann-La Roche Hybridon...
12:00 AM, Jun 28, 1993  |  BioCentury | Product Development

Ecogen ramping up nematode program

Ecogen ramping up nematode program Ecogen Inc. is gearing up to begin research directed at the commercial development of nematode technology it acquired last year from Bioenterprises Pty Ltd. of Australia....
12:00 AM, Jun 28, 1993  |  BioCentury | Politics, Policy & Law

BIO still mulling orphan drug compromise

BIO still mulling orphan drug compromise The Biotechnology Industry Organization hopes to discuss its proposed Orphan Drug Act compromise bill at the next executive board meeting at the end of the month, according to spokesperson...
12:00 AM, Jun 28, 1993  |  BioCentury | Strategy

Adagene finds $3M angel

Adagene Inc., which is developing consumer market applications for recombinant lactoferrin, was to announce this week that it has completed a $3 million first round financing from a single private investor, Gordon Cain, of Houston. ...

Pages